Description
Compound C108 is a G3BP2 inhibitor. Compound C108 also targeted stress granule-associated proteins and Gtpase-activating protein (SH3 domain) binding protein 2. Compound C108 potently inhibits esophageal squamous cell carcinoma (ESCC) cell metastasisIn VitroCompound C108 (1 µM; 24 h) shows anti-tumor activity against BT474 cells. Compound C108 (4 µM; 24 h) significantly decreases the protein expression of G3BP2 in G3BP2 overexpressing KYSE410 cells and LINC01554 transfected KYSE30 cells. Compound C108 (4 µM; 24 h) attenuates ESCC cell metastasis, migration and invasion in KYSE410, KYSE30 and KYSE150 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: G3BP2-overexpressing KYSE410 cells, LINC01554-transfected KYSE30 cells Concentration: 4 µM Incubation Time: 24 h Result: Decreased the protein level of G3BP2 and HDGF.In VivoCompound C108 (1 µM; 24 h) targets and decreases tumor initiating cells (TICs), while injected BT-474 cells treated with Compound C108 into the mammary fat pad of female nonobese diabetic/severe combined immune deficiency (NOD-SCID) mice in a limiting-dilution xenograft assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:G3BP2